Korea Future Management is to discover and honor
the people, companies, and organizations who have outstanding competence in
various section of the society, which is organized by The Korea Herald, and
Herald Economy, and supervised by Power Korea Monthly, in order to widely
broadcast such group of people. NKCL Bio Group has been ranked with major
companies that represent Korea and awarded together with outstanding companies
like Starbucks, GS Retail, etc.
NKCL is a Korean Bio-company that research
and develops NK immunocyte treatment using NK immune cells, which are widely
seen as one of the driving forces of the fourth next-generation industry.
Through its differentiated technology
competitiveness, NKCL Bio Group is targeting the $100 billion immune cell
therapy market. In particular, the group is focusing on popularizing NK immune cell
therapy by expanding facilities and systems of NK cell culture automation
system in which artificial intelligence (AI) is applied. Reflecting the ‘Untact’
era, the GMP automation system can prevent human error in advance by
controlling the incubation process with artificial intelligence while at the
same time blocking the external threats such as virus infection, and can block
the outflow of high-tech due to manpower outflow. This solves the scarcity of
advanced personnel at the cultivation center, and increases productivity by
more than 100 times which vastly decreases the production cost.
Earlier this year, the company also carried
out active overseas projects with the aim of expanding to the global market. It
made inroads into overseas markets with the same direction as in Korea,
including hospital business in Qingdao, China, brand promotion and business in
Hollywood, the U.S., and the establishment of GMP in Jakarta, Indonesia.
After the Corona was expanded, the company
is focusing on domestic activities that were carried out simultaneously with
its overseas business. In Korea, hospitals in Suwon, Gwangju, and Gimpo,
Gyeonggi Province, are in the process of preparing necessary for immuno-cell
therapy after signing MOA with NKCL, and NKCL continues to select cooperative
partners among domestic hospitals that want to collaborate on immuno-cell
treatment. In addition, about 60 NKCL Immune Cafes and NKCL Immune Care Centers
will be established in various parts of the country under the theme of programs
and products that boost immunity, and 10 in Seoul, 5 in Gyeonggi Province, and
8 in Busan have already signed contracts with applicants from different
regions.
In this time when personal health and
immunity is the most important concern, NKCL Bio Group is focusing on NKCL
branding, releasing a series of products that show technology, color and
identity. Products include: ‘NK Blue Bio recombination Cream & Fill mask’, ‘NK
Immune Toner, Cream and Serum’, ‘NK microfilm and NK Dual Effect Regen Pack’,
‘NK Cordycep Gold 300’ and ‘NK Rest Brain’. Various immunity boosting products
will be introduced.
NKCL Bio Group is focusing on solidifying
domestic infrastructure in the second half of 2020, and the next goal is to
establish the 2nd GMP automated culture center, NKCL anti-aging center and NKCL
anti-cancer center. In addition, we are constantly devoting our energies to
research to realize the vision of establishing an international center by
applying the proven system to many countries around the world.
News Link: http://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202008110266&t=NN